
|Articles|March 1, 2003
Benefits of PDT more far-reaching than previously expected
Orlando-Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics) is used widely to treat predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration (AMD). The therapy, however, has met clinician resistance for treating occult CNV despite good visual results in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Trial, according to Joan W. Miller, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























